Differential management of mild-to-severe psoriasis with biologic drugs: An Italian Delphi consensus expert panel
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Differential management of mild-to-severe psoriasis with biologic drugs: An Italian Delphi consensus expert panel
Authors
Keywords
-
Journal
JOURNAL OF DERMATOLOGICAL TREATMENT
Volume 26, Issue 2, Pages 128-133
Publisher
Informa UK Limited
Online
2014-04-08
DOI
10.3109/09546634.2014.907466
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab
- (2013) Viviana Lora et al. IMMUNOLOGIC RESEARCH
- Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis
- (2013) S. Fénix-Caballero et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Which Antipsoriatic Drug Has the Fastest Onset of Action?—Systematic Review on the Rapidity of the Onset of Action
- (2013) Alexander Nast et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Incidence of Cardiovascular Disease in Individuals with Psoriasis: A Systematic Review and Meta-Analysis
- (2013) Eleanor J. Samarasekera et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
- (2013) Iain B McInnes et al. LANCET
- The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis
- (2012) Sandra Garcês et al. ANNALS OF THE RHEUMATIC DISEASES
- Association Between Tumor Necrosis Factor Inhibitor Therapy and Myocardial Infarction Risk in Patients With Psoriasis
- (2012) Jashin J. Wu et al. ARCHIVES OF DERMATOLOGY
- Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry
- (2012) Fabiola Atzeni et al. AUTOIMMUNITY REVIEWS
- Placental Transfer of Anti–Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel Disease
- (2012) Uma Mahadevan et al. Clinical Gastroenterology and Hepatology
- Efficacy and Safety of Subcutaneous Anti-Tumor Necrosis Factor-Alpha Agents, Etanercept and Adalimumab, in Elderly Patients Affected by Psoriasis and Psoriatic Arthritis: An Observational Long-Term Study
- (2012) Maria Esposito et al. DERMATOLOGY
- The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial)
- (2012) Robert Strohal et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
- (2012) Rosa Parisi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Drug Dosing Based on Weight and Body Surface Area: Mathematical Assumptions and Limitations in Obese Adults
- (2012) Manjunath P. Pai PHARMACOTHERAPY
- Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150 000 pregnant women and expectant fathers
- (2012) KK Viktil et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- Patients with Psoriasis Have a Higher Prevalence of Parental Cardiovascular Disease
- (2011) Paolo Gisondi et al. DERMATOLOGY
- Safety of infliximab use during pregnancy
- (2011) Nada Djokanovic et al. REPRODUCTIVE TOXICOLOGY
- Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review
- (2011) A. M. G. Brunasso et al. RHEUMATOLOGY
- Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study
- (2010) A. Jamnitski et al. ANNALS OF THE RHEUMATIC DISEASES
- No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register
- (2010) Mark Lunt et al. ARTHRITIS AND RHEUMATISM
- Acute infusion reactions induced by monoclonal antibody therapy
- (2010) Enrico Maggi et al. Expert Review of Clinical Immunology
- Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations
- (2010) Mark Lebwohl et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
- (2009) W. G. Dixon et al. ANNALS OF THE RHEUMATIC DISEASES
- Long-term Course of Demyelinating Neuropathies Occurring During Tumor Necrosis Factor-α–Blocker Therapy
- (2009) Pierre Lozeron et al. ARCHIVES OF NEUROLOGY
- Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry
- (2009) F. Tubach et al. ARTHRITIS AND RHEUMATISM
- Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
- (2009) Alice Gottlieb et al. LANCET
- Tumor necrosis factor-α antagonist use and heart failure in elderly patients with rheumatoid arthritis
- (2008) Soko Setoguchi et al. AMERICAN HEART JOURNAL
- Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis
- (2008) B. Strober et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- (2008) Craig L Leonardi et al. LANCET
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
- (2008) Kim A Papp et al. LANCET
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
- (2007) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started